Sample Size Estimation of Multiregional Clinical Trials with Heterogeneous Variability Across Regions

被引:5
|
作者
Wu, Yuh-Jenn [1 ]
Tan, Te-Sheng [2 ]
Chow, Shein-Chung [3 ]
Hsiao, Chin-Fu [2 ,4 ]
机构
[1] Chung Yuan Christian Univ, Dept Appl Math, Chungli, Taiwan
[2] Natl Hlth Res Inst, Div Biostat & Bioinformat, Inst Populat Hlth Sci, Zhunan Town 350, Miaoli County, Taiwan
[3] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA
[4] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Clin Trial Stat, Zhunan Town, Miaoli County, Taiwan
关键词
Multiregional clinical trial; Bridging study; Consistent trend; ETHNIC-DIFFERENCES; POPULATION;
D O I
10.1080/10543406.2013.859150
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, global collaboration has become a conventional strategy for new drug development. To accelerate the development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries around the world under the same protocol. After showing the overall efficacy of a drug in all global regions, one can also simultaneously evaluate the possibility of applying the overall trial results to all regions and subsequently support drug registration in each of them. Several statistical methods have been proposed for the design and evaluation of MRCTs. Most of these approaches, however, assume a common variability of the primary endpoint across regions. In practice, this assumption may not be true, due to differences across regions (e.g., differences in ethnic factors and/or medical culture/practice). In this article, we use a random-effect model for modeling heterogeneous variability across regions for the design and evaluation of MRCTs. We also address consideration on the determination of the number of subjects in a specific region to establish the consistency of treatment effects between the specific region and the entire group.
引用
收藏
页码:254 / 271
页数:18
相关论文
共 50 条
  • [41] Sample size re-estimation for response-adaptive randomized clinical trials
    Li, Xin
    Hu, Feifang
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 1058 - 1073
  • [42] Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint
    Xie, TL
    Waksman, J
    STATISTICS IN MEDICINE, 2003, 22 (18) : 2835 - 2846
  • [43] Sample size re-estimation for covariate-adaptive randomized clinical trials
    Li, Xin
    Ma, Wei
    Hu, Feifang
    STATISTICS IN MEDICINE, 2021, 40 (12) : 2839 - 2858
  • [44] Blinded sample size re-estimation in clinical trials comparing several treatments
    Govindarajulu, Z.
    STATISTICS, 2011, 45 (06) : 575 - 591
  • [45] Robustness of sample size re-estimation procedure in clinical trials (arbitrary populations)
    Govindarajulu, Z
    STATISTICS IN MEDICINE, 2003, 22 (11) : 1819 - 1828
  • [46] Sample Size Estimation in Clinical Research From Randomized Controlled Trials to Observational Studies
    Wang, Xiaofeng
    Ji, Xinge
    CHEST, 2020, 158 (01) : S12 - S20
  • [47] Sample size re-estimation for survival data in clinical trials with an adaptive design
    Togo, Kanae
    Iwasaki, Manabu
    PHARMACEUTICAL STATISTICS, 2011, 10 (04) : 325 - 331
  • [48] On Cost Effectiveness and Sample Size in Clinical Trials
    Augustinus A. M. Hart
    Marcel G. W. Dijkgraaf
    PharmacoEconomics, 2004, 22 : 685 - 688
  • [49] Sample size and clinical trials in pediatric resuscitation
    Edmunds, Katherine
    Zhang, Yin
    Kerrey, Benjamin T.
    JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2021, 2 (04)
  • [50] The proper sample size in clinical orthopedic trials
    Brocai, DRC
    Lukoschek, M
    Hartmann, M
    Loew, M
    ORTHOPADE, 1998, 27 (05): : 301 - 304